The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Results from a Phase I/II trial of pirtobrutinib and LV20.19 for patients with R/R lymphomas
Fateeha Furqan, MD, Medical College of Wisconsin, Milwaukee, WI, presents the results of a Phase I/II trial (NCT04186520) of pirtobrutinib, a non-covalent BTK inhibitor, combined with LV20.19, a lentiviral transduced bispecific anti-CD20/CD19 CAR T-cell, to improve outcomes in patients with relapsed/refractory (R/R) lymphomas. Whilst immunophenotyping was similar between groups that received LV20.19 monotherapy and in combination with pirtobrutinib, the pirtobrutinib group had a stronger, although not statistically significant, polyfunctional strength index. The overall response rate (ORR) in that group was 82%, with some grade 1 or 2 cytokine release syndromes (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated HLH-like syndromes (IEC-HS). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
